Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy
<p>Abstract</p> <p>Background</p> <p>Bcl-2 is positively regulated by hormonal receptor pathways in breast cancer. A study was conducted to assess the prognostic significances of clinico-pathologic variables and of ER, PR, p53, c-erbB2, bcl-2, or Ki-67 as markers of rel...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2007-04-01
|
| Series: | BMC Cancer |
| Online Access: | http://www.biomedcentral.com/1471-2407/7/63 |
| _version_ | 1828217748366295040 |
|---|---|
| author | Kim Dong-Wan Han Wonshik Chie Eui Lee Se-Hoon Oh Do-Youn Im Seock-Ah Lee Kyung-Hun Kim Tae-You Park In Noh Dong-Young Heo Dae Ha Sung Bang Yung-Jue |
| author_facet | Kim Dong-Wan Han Wonshik Chie Eui Lee Se-Hoon Oh Do-Youn Im Seock-Ah Lee Kyung-Hun Kim Tae-You Park In Noh Dong-Young Heo Dae Ha Sung Bang Yung-Jue |
| author_sort | Kim Dong-Wan |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background</p> <p>Bcl-2 is positively regulated by hormonal receptor pathways in breast cancer. A study was conducted to assess the prognostic significances of clinico-pathologic variables and of ER, PR, p53, c-erbB2, bcl-2, or Ki-67 as markers of relapse in breast cancer patients who had received the identical adjuvant therapy at a single institution.</p> <p>Methods</p> <p>A cohort of 151 curatively resected stage III breast cancer patients (M:F = 3:148, median age 46 years) who had 4 or more positive lymph nodes and received doxorubicin and cyclophosphamide followed by paclitaxel (AC/T) as adjuvant chemotherapy was analyzed for clinico-pathologic characteristics including disease-free survival (DFS) and overall survival (OS). Patients with positive ER and/or PR expression received 5 years of tamoxifen following AC/T. The protein expressions of biomarkers were assessed immunohistochemically.</p> <p>Results</p> <p>The median follow-up duration was 36 months, and 37 patients (24.5%) experienced a recurrence. Univariate analyses indicated that the tumor size (<it>P </it>= 0.038) and the number of involved lymph nodes (<it>P </it>< 0.001) significantly affected the recurrences. However, the type of surgery, the histology, histologic grade, the presence of endolymphatic emboli, and a close resection margin did not. Moreover, ER positivity (<it>P </it>= 0.013), bcl-2 positivity (<it>P </it>= 0.002) and low p53 expression (<it>P </it>= 0.032) were found to be significantly associated with a prolonged DFS. Furthermore, multivariate analysis identified 10 or more involved lymph nodes (HR 7.366; <it>P </it>< 0.001), negative bcl-2 expression (HR 2.895; <it>P </it>= 0.030), and c-erbB2 over-expression (HR 3.535; <it>P </it>= 0.001) as independent indicators of poorer DFS. In addition, bcl-2 expression was found to be significantly correlated with the expressions of ER and PR, and inversely correlated with the expressions of p53, c-erbB2 and Ki-67. Patients with bcl-2 expression had a significantly longer DFS than those without, even in the ER (+) subgroup. Moreover, OS was significantly affected by ER, bcl-2 and c-erbB2.</p> <p>Conclusion</p> <p>Bcl-2 is an independent prognostic factor of DFS in curatively resected stage III breast cancer patients and appears to be a useful prognostic factor in combination with c-erbB2 and the number of involved lymph nodes.</p> |
| first_indexed | 2024-04-12T15:51:31Z |
| format | Article |
| id | doaj.art-338bf790b1d045d6ac90147e6025ad48 |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-04-12T15:51:31Z |
| publishDate | 2007-04-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-338bf790b1d045d6ac90147e6025ad482022-12-22T03:26:28ZengBMCBMC Cancer1471-24072007-04-01716310.1186/1471-2407-7-63Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapyKim Dong-WanHan WonshikChie EuiLee Se-HoonOh Do-YounIm Seock-AhLee Kyung-HunKim Tae-YouPark InNoh Dong-YoungHeo DaeHa SungBang Yung-Jue<p>Abstract</p> <p>Background</p> <p>Bcl-2 is positively regulated by hormonal receptor pathways in breast cancer. A study was conducted to assess the prognostic significances of clinico-pathologic variables and of ER, PR, p53, c-erbB2, bcl-2, or Ki-67 as markers of relapse in breast cancer patients who had received the identical adjuvant therapy at a single institution.</p> <p>Methods</p> <p>A cohort of 151 curatively resected stage III breast cancer patients (M:F = 3:148, median age 46 years) who had 4 or more positive lymph nodes and received doxorubicin and cyclophosphamide followed by paclitaxel (AC/T) as adjuvant chemotherapy was analyzed for clinico-pathologic characteristics including disease-free survival (DFS) and overall survival (OS). Patients with positive ER and/or PR expression received 5 years of tamoxifen following AC/T. The protein expressions of biomarkers were assessed immunohistochemically.</p> <p>Results</p> <p>The median follow-up duration was 36 months, and 37 patients (24.5%) experienced a recurrence. Univariate analyses indicated that the tumor size (<it>P </it>= 0.038) and the number of involved lymph nodes (<it>P </it>< 0.001) significantly affected the recurrences. However, the type of surgery, the histology, histologic grade, the presence of endolymphatic emboli, and a close resection margin did not. Moreover, ER positivity (<it>P </it>= 0.013), bcl-2 positivity (<it>P </it>= 0.002) and low p53 expression (<it>P </it>= 0.032) were found to be significantly associated with a prolonged DFS. Furthermore, multivariate analysis identified 10 or more involved lymph nodes (HR 7.366; <it>P </it>< 0.001), negative bcl-2 expression (HR 2.895; <it>P </it>= 0.030), and c-erbB2 over-expression (HR 3.535; <it>P </it>= 0.001) as independent indicators of poorer DFS. In addition, bcl-2 expression was found to be significantly correlated with the expressions of ER and PR, and inversely correlated with the expressions of p53, c-erbB2 and Ki-67. Patients with bcl-2 expression had a significantly longer DFS than those without, even in the ER (+) subgroup. Moreover, OS was significantly affected by ER, bcl-2 and c-erbB2.</p> <p>Conclusion</p> <p>Bcl-2 is an independent prognostic factor of DFS in curatively resected stage III breast cancer patients and appears to be a useful prognostic factor in combination with c-erbB2 and the number of involved lymph nodes.</p>http://www.biomedcentral.com/1471-2407/7/63 |
| spellingShingle | Kim Dong-Wan Han Wonshik Chie Eui Lee Se-Hoon Oh Do-Youn Im Seock-Ah Lee Kyung-Hun Kim Tae-You Park In Noh Dong-Young Heo Dae Ha Sung Bang Yung-Jue Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy BMC Cancer |
| title | Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy |
| title_full | Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy |
| title_fullStr | Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy |
| title_full_unstemmed | Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy |
| title_short | Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy |
| title_sort | prognostic significance of bcl 2 expression in stage iii breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy |
| url | http://www.biomedcentral.com/1471-2407/7/63 |
| work_keys_str_mv | AT kimdongwan prognosticsignificanceofbcl2expressioninstageiiibreastcancerpatientswhohadreceiveddoxorubicinandcyclophosphamidefollowedbypaclitaxelasadjuvantchemotherapy AT hanwonshik prognosticsignificanceofbcl2expressioninstageiiibreastcancerpatientswhohadreceiveddoxorubicinandcyclophosphamidefollowedbypaclitaxelasadjuvantchemotherapy AT chieeui prognosticsignificanceofbcl2expressioninstageiiibreastcancerpatientswhohadreceiveddoxorubicinandcyclophosphamidefollowedbypaclitaxelasadjuvantchemotherapy AT leesehoon prognosticsignificanceofbcl2expressioninstageiiibreastcancerpatientswhohadreceiveddoxorubicinandcyclophosphamidefollowedbypaclitaxelasadjuvantchemotherapy AT ohdoyoun prognosticsignificanceofbcl2expressioninstageiiibreastcancerpatientswhohadreceiveddoxorubicinandcyclophosphamidefollowedbypaclitaxelasadjuvantchemotherapy AT imseockah prognosticsignificanceofbcl2expressioninstageiiibreastcancerpatientswhohadreceiveddoxorubicinandcyclophosphamidefollowedbypaclitaxelasadjuvantchemotherapy AT leekyunghun prognosticsignificanceofbcl2expressioninstageiiibreastcancerpatientswhohadreceiveddoxorubicinandcyclophosphamidefollowedbypaclitaxelasadjuvantchemotherapy AT kimtaeyou prognosticsignificanceofbcl2expressioninstageiiibreastcancerpatientswhohadreceiveddoxorubicinandcyclophosphamidefollowedbypaclitaxelasadjuvantchemotherapy AT parkin prognosticsignificanceofbcl2expressioninstageiiibreastcancerpatientswhohadreceiveddoxorubicinandcyclophosphamidefollowedbypaclitaxelasadjuvantchemotherapy AT nohdongyoung prognosticsignificanceofbcl2expressioninstageiiibreastcancerpatientswhohadreceiveddoxorubicinandcyclophosphamidefollowedbypaclitaxelasadjuvantchemotherapy AT heodae prognosticsignificanceofbcl2expressioninstageiiibreastcancerpatientswhohadreceiveddoxorubicinandcyclophosphamidefollowedbypaclitaxelasadjuvantchemotherapy AT hasung prognosticsignificanceofbcl2expressioninstageiiibreastcancerpatientswhohadreceiveddoxorubicinandcyclophosphamidefollowedbypaclitaxelasadjuvantchemotherapy AT bangyungjue prognosticsignificanceofbcl2expressioninstageiiibreastcancerpatientswhohadreceiveddoxorubicinandcyclophosphamidefollowedbypaclitaxelasadjuvantchemotherapy |